July 08, 2025

Orforglipron Lowers A1c, Weight in T2D Patients 

A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.

Conexiant

July 08, 2025

Weekly Efsitora Matches Glargine in HbA1c Control

The regimen also showed lower hypoglycemia rates in insulin-naive adults with type 2 diabetes.

Conexiant

July 07, 2025

FDA Approves First Oral Hereditary Angioedema Treatment

FDA approves Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema, shown in trials to provide faster symptom relief and eliminate the need for injection.

Conexiant

July 03, 2025

3 things you missed in government this week

ADA News is providing a roundup of government happenings you may have missed this week.

ADA News

July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

July 01, 2025

FDA Approves Low-IgA IG Therapy

GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 26, 2025

First Targeted Therapy Approved for BP

The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.

Conexiant

June 26, 2025

Medical Groups Unite on Vaccine Policy

Major medical associations jointly reaffirm commitment to respiratory virus vaccines amid federal immunization review process changes.

Conexiant